Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02985840 · ClinicalTrials.gov registry record · Phase 4

Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department

A Phase 4 study, sponsored by OhioHealth.

Terminated
Registry status
Phase 4
Development phase
127
Enrollment target

NCT02985840 is a Phase 4 study that was terminated before completion, run by OhioHealth. The registered enrollment target is 127 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02985840, a Phase 4 study, was terminated before completion, sponsored by OhioHealth.

TERMINATED
Registry status
Phase 4
Development phase
127 participants
Enrollment target

Study Summary

Nausea is a common complaint in patients who present to the emergency department (ED). Although the number of conditions that can present with nausea are numerous, the mainstay of treatment has become intravenous ondansetron (Zofran), not only due to its rapid onset but also its availability. One of the major drawbacks to using this form is that it often needs to be redosed. This study aims to compare intravenous (IV) ondansetron alone versus IV ondansetron given with IV dexamethasone (Decadron) as another viable option when treating patients with nausea in the emergency department. Previous studies in patients undergoing surgical procedures have shown that when IV dexamethasone is given with IV ondansetron to post-operative patients they have less nausea and vomiting than ondansetron alone, and were even found to show decreased post-operative pain associated with nausea. It has also been shown to decrease the need to re-dose antiemetic medication. Although this combination has not been tested in the emergency department it is believed by these investigators that the additional use of dexamethasone may decrease the need to use repeated doses of ondansetron. The investigators believe this may change the way physicians currently approach the nauseated patient in regards to treatment. That rather than possibly giving multiple doses of one medication over and over to reduce a patient's nausea, physicians can give two medications together at one time. The investigators hope to demonstrate that by giving intravenous dexamethasone and ondansetron together, it may be possible to reduce the number of patients who need additional doses of nausea medication.

Interventions

  • DRUG Dexamethasone
  • DRUG Ondansetron

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2014-01-28
Est. Completion 2016-11-15
Phase Phase 4

Sponsor

OhioHealth

20 total trials

What the Registry Record Tells You About NCT02985840

The ClinicalTrials.gov registry entry for NCT02985840 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OhioHealth, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.

NCT02985840 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02985840 about?

NCT02985840 is a clinical study titled "Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department". Nausea is a common complaint in patients who present to the emergency department (ED). Although the number of conditions that can present with nausea are numerous, the mainstay of treatment has become intravenous ondansetron (Zofran), not only due to its rapid onset but also its availability. One of...

What is the current status of trial NCT02985840?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2014-01-28. Estimated completion is 2016-11-15.

What interventions are being tested in trial NCT02985840?

The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG).

Who is sponsoring clinical trial NCT02985840?

This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.